Article

Adherence to the medical regimen during the first two years after lung transplantation.

1 Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Transplantation (Impact Factor: 3.78). 02/2008; 85(2):193-202. DOI: 10.1097/TP.0b013e318160135f
Source: PubMed

ABSTRACT Despite the importance of adherence to the medical regimen for maximizing health after lung transplantation, no prospective studies report on rates or risk factors for nonadherence in this patient population. Whether adherence levels differ in lung versus other types of transplant recipients is unknown.
A total of 178 lung recipients and a comparison group of 126 heart recipients were enrolled. Adherence in nine areas was assessed in separate patient and family caregiver interviews 2, 7, 12, 18, and 24 months posttransplant. Potential risk factors for nonadherence were obtained at the initial assessment.
Cumulative incidence rates of persistent nonadherence (i.e., nonadherence at > or =2 consecutive assessments) were significantly lower (P<0.05) in lung recipients than heart recipients for taking immunosuppressants (13% nonadherent vs. 21%, respectively), diet (34% vs. 56%), and smoking (1% vs. 8%). Lung recipients had significantly higher persistent nonadherence to completing blood work (28% vs. 17%) and monitoring blood pressure (70% vs. 59%). They had a high rate of spirometry nonadherence (62%; not measured in heart recipients). The groups did not differ in nonadherence to attending clinic appointments (27%), exercise (44%), or alcohol limitations (7%). In both groups, poor caregiver support and having only public insurance (e.g., Medicaid) increased nonadherence risk in all areas.
Lung recipients were neither uniformly better nor worse than heart recipients in adhering to their regimen. Lung recipients have particular difficulty with some home monitoring activities. Strategies to maximize adherence in both groups should build on caregiver support and on strengthening financial resources for patient healthcare requirements.

0 Bookmarks
 · 
91 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although medication non-adherence (MNA) is a major risk factor for poor outcomes, the evolution of MNA from pre- to 3 years post-transplant among the 4 major organ transplant groups is unknown. Therefore, this study described this evolution and investigated whether pre-transplant MNA predicts post-transplant immunosuppressive medication non-adherence (IMNA). Adult participants (single transplant, pre-transplant and ≤ 1 post-transplant assessment, using medications pre-transplant) in the Swiss Transplant Cohort Study (a prospective nation-wide cohort study) were included. Non-adherence, defined as any deviation from dosing schedule, was assessed using two self-report questions pre-transplant and at 6, 12, 24, and 36 months post-transplant. Non-adherence patterns were modelled using generalized estimating equations. The sample included 1505 patients (average age: 52.5 years (SD: 13.1); 36.3% females; 924 renal, 274 liver, 181 lung, 126 heart). The magnitude and variability of self-reported MNA decreased significantly from pre-transplant to 6 months post-transplant (OR=0.21; 95%CI: 0.16-0.27). Post-transplant IMNA increased continuously from 6 months to 3 years post-transplant (OR=2.75; 95%CI: 1.97-3.85). Pre-transplant MNA was associated with threefold higher odds of post-transplant IMNA (OR=3.10; 95%CI: 2.29-4.21). As pre-transplant MNA predicted post-transplant IMNA and a continuous increase in post-transplant IMNA was observed, early adherence-supporting interventions are indispensible. This article is protected by copyright. All rights reserved.
    Transplant International 03/2014; · 3.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Accurate immunosuppression is of critical importance in preventing rejection, while avoiding toxicity following lung transplantation. The mainstay immunosuppressants are calcineurin inhibitors, which require regular monitoring due to interactions with other medications and diet. Adherence to immunosuppression and patient knowledge is vital and can be improved through patient education. Education using tablet-computers was investigated. To compare tablet-PC education and conventional education in improving immunosuppression trough levels in target range 6 months after a single education. Secondary parameters were ratio of immunosuppression level measurements divided by per protocol recommended measurements, time and patient satisfaction regarding education. Single-centre, open labelled randomised controlled trial. Patients >6 months after lung-transplantation with <50% of calcineurin inhibitor trough levels in target range. Tablet-pc education versus personal, nurse-led education. Calcineurin inhibitor levels in target range 6 months after education, level variability, interval adherence, knowledge and adherence was studied. As outcome parameter, renal function was measured and adverse events registered. Sixty-four patients were 1:1 randomised for either intervention. Levels of immunosuppression 6 months after education were equal (tablet-PC 58% vs. conventional 48%, p = 0.27), both groups improved in achieving a CNI trough level within target range by either education method (delta tablet-PC 29% vs. conventional 20%). In all patients, level variability decreased (-20.4%), whereas interval adherence remained unchanged. Knowledge about immunosuppression improved by 7% and compliance tests demonstrated universal improvements with no significant difference between groups. Education is a simple, effective tool in improving adherence to immunosuppression. Tablet-PC education was non-inferior to conventional education. ClinicalTrials.gov NCT01398488 http://clinicaltrials.gov/ct2/show/NCT01398488?term=gottlieb+tablet+pc+education&rank=1.
    PLoS ONE 01/2014; 9(3):e90828. · 3.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Although lung transplantation improves quality of life, most psychosocial research focuses on adverse psychological and social functioning outcomes. Positive effects, particularly in the late-term years as physical morbidities increase, have received little attention. We provide the first data on a psychological benefit – post-traumatic growth (PTG) – and we focused on long-term (>5 yr) survivors.Methods Among 178 patients from a prospective study of mental health during the first two yr post-transplant, we recontacted survivors 6–11 yr post-transplant. We assessed PTG (i.e., positive psychological change resulting from the transplant) and examined its relationship to other patient characteristics with multivariable regression analyses.ResultsSixty-four patients (86% of survivors) were assessed (M = 8.1 yr post-transplant, SD = 1.2). Mean PTG exceeded the scale's midpoint (M = 38.6, SD = 10.0; scale midpoint = 25). Recipients experiencing greater PTG were female (p = 0.022), less educated (p = 0.014), and had a history of post-transplant panic disorder (p = 0.005), greater friend support (p = 0.048), and better perceived health (p = 0.032). Neither other pre- or post-transplant mood and anxiety disorders nor transplant-related morbidities (acute rejection, bronchiolitis obliterans syndrome) predicted PTG.ConclusionsPTG exceeded levels observed in other chronic disease populations, suggesting that lung transplantation may uniquely foster positive psychological change in long-term survivors. PTG occurs despite physical and psychiatric morbidities. Whether PTG promotes other positive post-transplant psychosocial outcomes deserves attention.
    Clinical Transplantation 04/2014; 28(4). · 1.63 Impact Factor

Full-text (2 Sources)

View
21 Downloads
Available from
May 20, 2014

Similar Publications